Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
OSTEOPORE LIMITED (OSX)ASX AI Signals has generated 13 signals for OSX during the last 90 days, indicating strong trading activity and ongoing AI monitoring
Latest OSX Signals | |
| 04/06/2026 | SELL |
| 03/06/2026 | BUY |
| 01/06/2026 | SELL |
OSX Share Price | |
| Current Price | $0.004 |
| 52 Week High | $0.026 |
| 52 Week Low: | $0.004 |
| Trading at (% of 52 Week High) | 15.38% |
Osteopore Limited (ASX: OSX) is a medical technology company specializing in the design and manufacture of regenerative implants using 3D-printed bioresorbable materials. The company focuses on solutions for bone and tissue repair across various surgical markets, including craniofacial, orthopedic, and dental applications. Osteopore’s products promote natural healing by supporting bone regrowth and gradually dissolving within the body.
The Health Care Equipment & Services sector on the ASX includes companies that produce medical devices, equipment, and supplies, as well as those providing healthcare-related services. This sector covers a wide range of products such as surgical instruments, diagnostic machines, and health monitoring devices. It also includes businesses involved in healthcare management, medical laboratories, and support services. These companies play a key role in supporting hospitals, clinics, and other healthcare providers to improve patient care. The sector is influenced by factors like technological advances, regulatory changes, and demand for healthcare services.
The SELL recommendation for OSTEOPORE LIMITED (OSX) is supported by the current low stock price indicating potential undervaluation risks and weak market sentiment. However, moderate confidence is maintained due to limited available financial data and potential volatility in microcap stocks.
Kelyniam Global Inc.
CANTON, Conn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Kelyniam Global, Inc. (OTC: KLYG), a leader in custom cranial and craniofacial implants, today announced it has secured an exclusive U.S. license from Evonik Industries AG to market VESTAKEEP® Fusion, a bi-calcium phosphate-infusLatest OSTEOPORE LIMITED(OSX) News
Kelyniam Global Secures Exclusive U.S. License for Evonik's VESTAKEEP® Fusion Biomaterial in Cranial Implants
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial